A pharmaceutical case of anaemia secondary to peptic ulcer disease in pregnancy

Abstract

Peptic ulcer disease (PUD) is a commonly encountered condition in primary care settings. A pregnant client (G4P3), presenting with anemia and a history of recurrent peptic ulcer disease (PUD), was assessed. Initial evaluation revealed pancytopenia, suggesting anemia secondary to PUD. Pharmaceutical care involved a comprehensive drug audit, considering potential drug-disease, drug-drug, drug-food, and drug-lifestyle interactions. The client was prescribed haematinics-astymin® and artemisinin-combination therapy (ACT) antimalarial (artemether-lumefantrine 80/480) in a spaced-out regimen. The client's response to intervention and overall drug audit resulted in improved economic and humanistic outcomes, demonstrating the value of comprehensive pharmaceutical care in managing complex cases.